PMID- 25196815
OWN - NLM
STAT- MEDLINE
DCOM- 20150107
LR  - 20181202
IS  - 1423-0232 (Electronic)
IS  - 0030-2414 (Linking)
VI  - 87
IP  - 5
DP  - 2014
TI  - The Epidermal Growth Factor Receptor Inhibitor-Related Skin Toxicity Index 
      (EGFRISTI): a new tool for grading and managing skin adverse reactions to 
      epidermal growth factor receptor inhibitors.
PG  - 311-9
LID - 10.1159/000365994 [doi]
AB  - BACKGROUND: Skin toxicity is frequent and debilitating in oncologic patients 
      treated with epidermal growth factor receptor inhibitors (EGFRIs). Grading and 
      management of skin adverse events (AEs) are poorly standardized. MATERIALS AND 
      METHODS: We developed a new score (EGFRISTI: Epidermal Growth Factor Receptor 
      Inhibitor-Related Skin Toxicity Index) which is able to quantify and monitor all 
      EGFRI-related dermatologic AEs over time. The utility of this tool was validated 
      in 130 patients treated with 5 different EGFRIs including both monoclonal 
      antibodies and tyrosine kinase inhibitors. RESULTS: The mean baseline EGFRISTI 
      score was 26.9 (range: 6.0-64.5). Mild toxicity was found in 55 patients (42.3%), 
      moderate toxicity in 43 (33.1%), and severe toxicity in 32 patients (24.6%). 
      After the first-line toxicity treatment, an EGFRISTI score reduction of >75% was 
      obtained in 31 patients (34.1%) and one of 50% in 40 patients (43.9%), while an 
      improvement of <50% was observed in the remaining 20 subjects (22.0%). 
      CONCLUSIONS: The EGFRISTI is a simple and reliable tool to quantify and express 
      the severity of all clinical signs and symptoms of EGFRI skin toxicity with a 
      single numerical value, to choose the most suitable therapy, and to measure its 
      efficacy.
CI  - (c) 2014 S. Karger AG, Basel.
FAU - Lisi, Paolo
AU  - Lisi P
AD  - Section of Clinical, Allergological and Venereological Dermatology, Department of 
      Medicine, University of Perugia, Perugia, Italy.
FAU - Bellini, Veronica
AU  - Bellini V
FAU - Bianchi, Leonardo
AU  - Bianchi L
LA  - eng
PT  - Journal Article
DEP - 20140829
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Acrodermatitis/chemically induced
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal/*adverse effects
MH  - Antineoplastic Agents/*adverse effects
MH  - ErbB Receptors/*antagonists & inhibitors
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Protein Kinase Inhibitors/*adverse effects
MH  - Skin Diseases/*chemically induced/therapy
EDAT- 2014/09/10 06:00
MHDA- 2015/01/08 06:00
CRDT- 2014/09/09 06:00
PHST- 2014/05/01 00:00 [received]
PHST- 2014/07/14 00:00 [accepted]
PHST- 2014/09/09 06:00 [entrez]
PHST- 2014/09/10 06:00 [pubmed]
PHST- 2015/01/08 06:00 [medline]
AID - 000365994 [pii]
AID - 10.1159/000365994 [doi]
PST - ppublish
SO  - Oncology. 2014;87(5):311-9. doi: 10.1159/000365994. Epub 2014 Aug 29.